Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt

by The Medical News • 2017/05/03 • 0 Comments

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay.

← Shire and Parion Sciences to collaborate on P-321 for ophthalmic indications

Pixium Vision et ses partenaires scientifiques annoncent de multiples progrès avec IRIS® et PRIMA pendant la conférence mondiale ARVO 2017 →

Post navigation